177 related articles for article (PubMed ID: 34693451)
1. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451
[TBL] [Abstract][Full Text] [Related]
2. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
3. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
5. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.
Ji XL; He M
Aging (Albany NY); 2019 Aug; 11(15):5848-5863. PubMed ID: 31422383
[TBL] [Abstract][Full Text] [Related]
6. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
7. Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.
Zuo D; Zhou Z; Wang H; Zhang T; Zang J; Yin F; Sun W; Chen J; Duan L; Xu J; Wang Z; Wang C; Lin B; Fu Z; Liao Y; Li S; Sun M; Hua Y; Zheng L; Cai Z
J Cell Mol Med; 2017 Feb; 21(2):208-221. PubMed ID: 27624867
[TBL] [Abstract][Full Text] [Related]
8. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.
Pan Y; Zhou F; Zhang R; Claret FX
PLoS One; 2013; 8(1):e54565. PubMed ID: 23382914
[TBL] [Abstract][Full Text] [Related]
9. Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma.
Zhong B; Shi D; Wu F; Wang S; Hu H; Cheng C; Qing X; Huang X; Luo X; Zhang Z; Shao Z
Cell Death Dis; 2019 Sep; 10(10):687. PubMed ID: 31534119
[TBL] [Abstract][Full Text] [Related]
10. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
12. Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.
He P; Wang Z; Sheng B; Xu Y; Feng S; Huang Y; Gong F; Tang L; Xie L
Histol Histopathol; 2020 Dec; 35(12):1511-1520. PubMed ID: 33372687
[TBL] [Abstract][Full Text] [Related]
13. Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy.
Yang R; Wang L; Sheng J; Huang Q; Pan D; Xu Y; Yan J; Wang X; Dong Z; Yang M
Arch Virol; 2019 Jul; 164(7):1805-1814. PubMed ID: 31087190
[TBL] [Abstract][Full Text] [Related]
14. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
15. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib.
Niehus SE; Tran DDH; Mischak M; Koch A
Cell Signal; 2018 Nov; 51():191-198. PubMed ID: 30075184
[TBL] [Abstract][Full Text] [Related]
17. Stattic Enhances Radiosensitivity and Reduces Radio-Induced Migration and Invasion in HCC Cell Lines through an Apoptosis Pathway.
Xu G; Zhu L; Wang Y; Shi Y; Gong A; Wu C
Biomed Res Int; 2017; 2017():1832494. PubMed ID: 29226125
[TBL] [Abstract][Full Text] [Related]
18. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
19. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
[TBL] [Abstract][Full Text] [Related]
20. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
